Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Healthy Volunteers (Non-alcoholic Steatohepatitis)
A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.
The study will investigate the influence of NNC0194-0499 on the blood levels of the two components of a birth control pill, Microgynon®.
- Trial name
- NCT06188026
- Testing
- NNC0194-0499, ethinylestradiol/levonorgestrel
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Fatty Liver Disease
Electrical Impedance Tomography in Fatty Liver Detection
Non-alcoholic fatty liver disease (NAFLD) is a condition where hepatocytes contain an abnormally high fat percentage. This condition is becoming increasingly common due to unhealthy food habits and sedentary lifestyle.
- Trial name
- NCT05189990
- Testing
- Electrical impedance tomography
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
NAFLD
Effect of Consumption of Millet Diet in Patients With NAFLD
With NAFLD fast rising its ranks in becoming a major non communicable disease in India and across the globe, this study aims at primary prevention of the condition.
- Trial name
- NCT06341790
- Testing
- jowar based products
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
NAFLD
NAFLD in Diabetes Type 2 in Primary Care
The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden.
- Trial name
- EPSONIP (NCT03864510)
- Where
- 2 sites in Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
NASH, NAFLD
Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for approximately 36% of liver-related deaths and over one…
- Trial name
- MODELS (NCT06888310)
- Testing
- extra blood sampling
- Where
- Italy
- Volunteers
- 408 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NAFLD
Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test
The Exalenz clinical investigation is a multicenter, non-randomized, blinded, study of the ¹³C-Octanaote breath test (OBT). The OBT is a non-invasive test for evaluation of disease severity in patients with suspected non…
- Trial name
- NCT01281059
- Testing
- BreathID - Breath Test - 13C Octanoate
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes…
- Trial name
- NCT07706010
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
Non-alcoholic Steatohepatitis (NASH)
Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH
The primary objectives of this study are to evaluate the effect of ESG with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) compared to LSG on 1) histological improvement in NASH; 2) all-cause mortality and liver-related…
- Trial name
- TESLA-NASH (NCT04060368)
- Testing
- Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications, Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Nonalcoholic Fatty Liver Disease
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
- Trial name
- NCT04766476
- Testing
- BMS-963272
- Where
- 19 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bristol-Myers Squibb
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Laparoscopic Sleeve Gastrectomy
Total Intravenous Anesthesia Versus Inhalation Anesthesia on Postoperative Liver Function
The pandemic of obesity has become a serious issue of public health worldwide as the size of the obese population has almost tripled over the last four decades and continues to riseزThe epidemic of obesity has led to a…
- Trial name
- NCT06423846
- Testing
- Total intravenous anesthesia group, sevoflurane group
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Benha University
Metabolic Associated Fatty Liver Disease
Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease
This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.
- Trial name
- NCT05913986
- Testing
- LUDLEV®300 mg/46.2 mg
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Saluz Investigación S. C.
Non-alcoholic Fatty Liver Disease, Obesity
The Influence of Autophagy on Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. It is not known why only some obese subjects develop NAFLD.
- Trial name
- NCT01988441
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- Far Eastern Memorial Hospital
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Prebiotics in Patients With Non-alcoholic Liver Disease
The purpose of this present study is to evaluating whether prebiotics - ITF (Inulin/OFS 75/25) is effective in treating patients with non-alcoholic liver disease.
- Trial name
- NCT02642172
- Testing
- ITF (Inulin/OFS 75/25)
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Kaplan Medical Center
Non Alcoholic Fatty Liver Disease
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
There is preliminary evidence that Omega 3, a compound naturally found in fish oil, reduces the amount of fat stored in the liver and improves liver function.
- Trial name
- NCT01277237
- Testing
- Omacor, lactose tablet
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Edinburgh
Non-Alcoholic Fatty Liver Disease
Efficacy of Phosphatidylcholine in NAFLD
This study evaluates efficacy of Phosphatidylcholine in addition to life style modification and patient health education by clinical Pharmacist in the Management of Non Alcoholic Fatty Liver NAFLD.
- Trial name
- NCT04411862
- Testing
- Phosphatidyl Choline, Lifestyle modification
- Volunteers
- 100 people
- Sponsor
- Nehal Abou Seada
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
The study investigators' aim is to determine the long term safety and efficacy of Metreleptin (Myalept,) in promoting amelioration of metabolic abnormalities in patients with all forms of partial lipodystrophy.
- Conditions
- Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT02654977
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.
NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity).
- Trial name
- NCT07900100
- Testing
- Rupatadin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.